

Company Number: 689455

JMCK Traumamed Limited
Abridged Unaudited Financial Statements
for the financial year ended 30 April 2025

JMCK Traumamed Limited
CONTENTS

	Page
Balance Sheet	3
Notes to the Financial Statements	4 - 6

JMCK Traumamed Limited

BALANCE SHEET

as at 30 April 2025

	Notes	2025 €	2024 €
Fixed Assets			
Tangible assets	5	2,111	3,074
Current Assets			
Debtors	6	184,610	155,007
Cash and cash equivalents		225,703	611,527
		410,313	766,534
Creditors: amounts falling due within one year	7	(142,144)	(169,607)
Net Current Assets		268,169	596,927
Total Assets less Current Liabilities		270,280	600,001
Capital and Reserves			
Called up share capital presented as equity		100	100
Retained earnings		270,180	599,901
Equity attributable to owners of the company		270,280	600,001

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

We as Directors of JMCK Traumamed Limited, state that -

(a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,

(b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied,

(c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),

(d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,

(e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

Approved by the board on 18 December 2025 and signed on its behalf by:

Joseph McKeever
Director

Brian McKeever
Director

JMCK Traumamed Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

1. General Information

JMCK Traumamed Limited is a company limited by shares incorporated and registered in Ireland. The registered number of the company is 689455. The registered office of the company is 8 Cherrywood, Loughlinstown, Co Dublin. The principal activity of the Company is the provision of medical services. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Statement of compliance

The financial statements of the company for the financial year ended 30 April 2025 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014.

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014 and Section 1A of FRS 102.

Turnover

Turnover comprises the invoice value of goods supplied by the company, exclusive of trade discounts and value added tax.

Tangible assets and depreciation

Tangible assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:

Fixtures, fittings and equipment	-	20% Straight line
----------------------------------	---	-------------------

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Employee benefits

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. The company also operates a defined benefit pension scheme for its employees providing benefits based on final pensionable pay. The assets of this scheme are also held separately from those of the company, being invested with pension fund managers.

JMCK Traumamed Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

Taxation and deferred taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the Balance Sheet date.

Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the Balance Sheet date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated at the rates of exchange ruling at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The resulting exchange differences are dealt with in the Profit and Loss Account.

Ordinary share capital

The ordinary share capital of the company is presented as equity.

3. Operating (loss)/profit	2025	2024
	€	€
Operating (loss)/profit is stated after charging:		
Depreciation of tangible assets	963	963
	<u> </u>	<u> </u>

4. Employees

The average monthly number of employees, including directors, during the financial year was 1, (2024 - 2).

	2025	2024
	Number	Number
Administration	-	1
Medical	1	1
	<u> </u>	<u> </u>
	1	2
	<u> </u>	<u> </u>

5. Tangible assets

	Fixtures, fittings and equipment	Total
	€	€
Cost		
At 1 May 2024	4,817	4,817
	<u> </u>	<u> </u>
At 30 April 2025	4,817	4,817
	<u> </u>	<u> </u>
Depreciation		
At 1 May 2024	1,743	1,743
Charge for the financial year	963	963
	<u> </u>	<u> </u>
At 30 April 2025	2,706	2,706
	<u> </u>	<u> </u>
Net book value		
At 30 April 2025	2,111	2,111
	<u> </u>	<u> </u>
At 30 April 2024	3,074	3,074
	<u> </u>	<u> </u>

JMCK Traumamed Limited
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
for the financial year ended 30 April 2025

6. Debtors	2025	2024
	€	€
Trade debtors	18,744	18,683
Other debtors	100,100	131,100
Taxation	65,766	5,224
	<u>184,610</u>	<u>155,007</u>
7. Creditors	2025	2024
Amounts falling due within one year	€	€
Taxation	129,847	139,221
Directors' current accounts (Note 9)	606	73
Accruals	11,691	30,313
	<u>142,144</u>	<u>169,607</u>
8. Income Statement	2025	2024
	€	€
At 1 May 2024	599,901	480,428
(Loss)/profit for the financial year	(329,721)	119,473
At 30 April 2025	<u>270,180</u>	<u>599,901</u>
9. Directors' remuneration and transactions	2025	2024
	€	€
Remuneration	277,546	279,583
Pension contributions	350,000	-
	<u>627,546</u>	<u>279,583</u>
The following amounts are repayable to the directors:	2025	2024
	€	€
Joseph McKeever	<u>606</u>	<u>73</u>

10. Post-Balance Sheet Events

There have been no significant events affecting the company since the financial year-end.

11. Approval of financial statements

The financial statements were approved and authorised for issue by the board of directors on 18 December 2025.